Stockscreener 앱 받기
86.67
1.08%
0.93
Dexcom Inc 주식(DXCM)의 최신 뉴스
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire
BGM and CGM Market is Set to Experience a Revolutionary Growth | Abbott Laboratories , Dexcom, Medtronic PLC - openPR.com
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga
Should You Be Excited About DexCom, Inc.'s (NASDAQ:DXCM) 24% Return On Equity? - simplywall.st
Goldman Sachs Initiates Coverage of DexCom (XTRA:DC4) with Buy Recommendation - Nasdaq
Goldman Sachs Initiates Coverage of DexCom (BIT:1DXCM) with Buy Recommendation - Nasdaq
DexCom (NASDAQ:DXCM) Now Covered by Analysts at The Goldman Sachs Group - Defense World
Goldman Sachs Initiates Coverage of DexCom (DXCM) with Buy Recommendation - Nasdaq
Goldman Sachs Initiates Coverage of DexCom (DXCM) With Buy Rating - MSN
Forecasting The Future: 7 Analyst Projections For DexCom - Benzinga
DexCom, Inc. (NASDAQ:DXCM) Q2 2024 Earnings Call Transcript - MSN
Jefferies Adjusts Price Target on DexCom to $110 From $105, Maintains Buy Rating - marketscreener.com
Goldman Sachs Initiates DexCom at Buy With $104 Price Target - marketscreener.com
DexCom (DXCM) Receives Positive Coverage with Growth Potential | - GuruFocus
DexCom (DXCM) Receives Positive Coverage with Growth Potential | DXCM Stock News - GuruFocus
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - The Globe and Mail
DexCom, Inc. (DXCM) Stock Analysis: 15.97% Potential Upside Amid Robust Analyst Support - DirectorsTalk Interviews
DexCom’s SWOT analysis: CGM leader faces supply challenges amid growth - Investing.com
DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move? - Smartkarma
An Intrinsic Calculation For DexCom, Inc. (NASDAQ:DXCM) Suggests It's 27% Undervalued - Yahoo Finance
Blood Glucose Monitoring (BGM) Devices Market Report 2025: Hospitals Lead in Blood Glucose Monitoring Device Usage, Home Care Grows Fastest - GlobeNewswire Inc.
DexCom (DXCM) Maintains Buy Rating as Price Target Raised to USD 102 | DXCM Stock News - GuruFocus
Citi Increases Price Target for DexCom (DXCM) to $102 | DXCM Sto - GuruFocus
Citi Increases Price Target for DexCom (DXCM) to $102 | DXCM Stock News - GuruFocus
Diabetic Care Device Market Set for Significant Growth with 10.1% CAGR - GlobeNewswire Inc.
Dexcom (DXCM) Gets a Buy from Wells Fargo - The Globe and Mail
DexCom adds Renée Galá to Board of Directors By Investing.com - Investing.com Nigeria
3 Big Reasons to Love DexCom (DXCM) - Yahoo Finance
The End Of The Diabetes Industry?Eli Lilly (NYSE:LLY), DexCom (NASDAQ:DXCM) - Benzinga
FDA Approves DexCom G4 Platinum Professional Continuous Glucose Monitoring System - Medical Product Outsourcing
Can DexCom, Inc. (NASDAQ:DXCM) Maintain Its Strong Returns? - Yahoo Finance
Here's Why You Should Add DexCom Stock to Your Portfolio Now - MSN
Dexcom CEO says CGMs fit MAHA agenda ‘very nicely’; Tandem preps for new products - MedTech Dive
Is DexCom, Inc. (NASDAQ:DXCM) Trading At A 24% Discount? - simplywall.st
Do Wall Street Analysts Like DexCom Stock? - Nasdaq
DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook - Yahoo Finance
Dexcom Beats Investor Claims Over Sales Growth Potential for Now - Bloomberg Law News
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil - TradingView
Dexcom Beats Investor Claims Over Growth Potential for Now (1) - Bloomberg Law News
DexCom, Inc. (DXCM) Announces Leadership Promotion: Jacob S. Lea - GuruFocus
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO | DXCM Stock News - GuruFocus
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO - GuruFocus
DexCom (DXCM) Elevates Jake Leach to President - GuruFocus
Dexcom promotes Jake Leach to president role - MassDevice
The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx - TradingView
Dexcom Promotes Jake Leach to Expanded President, COO Role - Medical Product Outsourcing
DexCom Adds President Role to COO Jake Leach - marketscreener.com
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy - Yahoo Finance
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns - TradingView
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case - MSN
DXCM STOCK NOTICE: Did DexCom, Inc. Commit Securities Fraud? Investors are Urged to Contact BFA Law about its Investigation if You Suffered Losses (DXCM) - ACCESS Newswire
0.10%
1.70%
자본화:
|
볼륨(24시간):